Lunai Bioworks Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067
Mailing Address CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES, CA, 90067
Phone 45 39179840
Fiscal Year End 0630
EIN 452259340
Financial Overview
FY2025
-$88.43M
Net Income
$163.13M
Total Assets
$31.15M
Total Liabilities
$131.98M
Stockholders' Equity
$-0.91
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 5, 2026 | View on SEC |
| 8-K Current report of material events | February 23, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | December 9, 2025 | View on SEC |
| 424B5 Prospectus supplement | December 3, 2025 | View on SEC |
| 8-K Current report of material events | December 3, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | November 28, 2025 | View on SEC |
| 8-K Current report of material events | November 25, 2025 | View on SEC |
Annual Reports
10-K September 29, 2025
- FDA approved early testing for their cancer drug (pre-clinical phase, 5+ years from market)
- Acquired AI drug-discovery startup Biosymetrics for $6M in stock
Material Events
8-K Acquisition March 30, 2026
High Impact
- Acquisition of Clemann Group IP to enable blood-brain barrier drug delivery
- Strategic pivot from service model to high-value proprietary drug developer
8-K Financial Distress March 5, 2026
High Impact
- Lunai Bioworks furloughed approximately 70% of its U.S. and Canadian workforce on February 27, 2026.
- The company faces a critical cash crunch with approximately $5 million in cash and cash equivalents and a $3 million monthly burn rate, providing a cash runway of less than two months.
8-K Financial Distress February 23, 2026
High Impact
- Lunai Bioworks Inc. (LNAI) received a Nasdaq delisting notice for failing to meet continued listing requirements.
- The company has appealed the decision, and a critical hearing is scheduled for March 26, 2026, which temporarily halts the delisting.
8-K Financial Distress February 12, 2026
High Impact
- Lunai Bioworks Inc. received a Nasdaq delisting notice due to its stock price falling below the $1.00 minimum bid requirement.
- The company does not qualify for the standard 180-day grace period because it executed a 1-for-10 reverse stock split on September 30, 2025.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.